Moderna Touts mRNA Progress, Plus $750m From Blackstone To Back Its Flu Vaccine

Moderna still projects $4.5bn in R&D spending this year for its pipeline of 28 mRNA vaccines, including a COVID-19 vaccine with stronger immune response than Spikevax.